Relay Therapeutics Inc (RLAY) recent activity suggests a positive outlook with the last week’s performance of -1.91%

Relay Therapeutics Inc (NASDAQ: RLAY) kicked off on Friday, up 7.71% from the previous trading day, before settling in for the closing price of $4.28. Over the past 52 weeks, RLAY has traded in a range of $4.25-$12.14.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

A company in the Healthcare sector has jumped its sales by 319.82% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded 9.40%. With a float of $121.92 million, this company’s outstanding shares have now reached $166.89 million.

In an organization with 323 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 58.64%, operating margin of -3926.55%, and the pretax margin is -3449.92%.

Relay Therapeutics Inc (RLAY) Insider and Institutional Ownership

Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Relay Therapeutics Inc is 27.16%, while institutional ownership is 73.16%. The most recent insider transaction that took place on Oct 28 ’24, was worth 9,823. In this transaction an insider of this company sold 1,621 shares at a rate of $6.06, taking the stock ownership to the 390,063 shares. Before that another transaction happened on Oct 28 ’24, when Company’s Chief Financial Officer sold 6,802 for $6.06, making the entire transaction worth $41,220. This insider now owns 306,391 shares in total.

Relay Therapeutics Inc (RLAY) Latest Financial update

Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.61 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around 9.40% per share during the next fiscal year.

Relay Therapeutics Inc (NASDAQ: RLAY) Trading Performance Indicators

Take a look at Relay Therapeutics Inc’s (RLAY) current performance indicators. Last quarter, stock had a quick ratio of 18.42. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 83.03.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.61, a number that is poised to hit -0.57 in the next quarter and is forecasted to reach -2.63 in one year’s time.

Technical Analysis of Relay Therapeutics Inc (RLAY)

Let’s dig in a bit further. During the last 5-days, its volume was 2.75 million. That was better than the volume of 1.49 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 18.40%. Additionally, its Average True Range was 0.31.

During the past 100 days, Relay Therapeutics Inc’s (RLAY) raw stochastic average was set at 5.56%, which indicates a significant decrease from 38.50% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 50.69% in the past 14 days, which was lower than the 91.51% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $5.83, while its 200-day Moving Average is $7.06. However, in the short run, Relay Therapeutics Inc’s stock first resistance to watch stands at $4.75. Second resistance stands at $4.89. The third major resistance level sits at $5.13. If the price goes on to break the first support level at $4.38, it is likely to go to the next support level at $4.14. The third support level lies at $4.00 if the price breaches the second support level.

Relay Therapeutics Inc (NASDAQ: RLAY) Key Stats

The company with the Market Capitalisation of 831.14 million has total of 167,383K Shares Outstanding. Its annual sales at the moment are 25,550 K in contrast with the sum of -341,970 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -92,210 K.